This product requires refrigeration and will ship with an ice pack.
High Strength Lactobacillus rhamnosus (LGG®)
Lactobacillus rhamnosus (LGG®) has been shown to or may:
- Reduce the incidence of eczema and food allergies in infants.1
- Reduce the frequency of diarrhoea.2
- Dairy free.
- A double blind, randomised placebo-controlled trial, in 159 mother-infant pairs measured the effect of LGG® in reducing the incidence of eczema and allergies in high risk infants. The mothers were given 20 billion LGG® organisms two to four weeks before expected delivery. For six months postnatally, LGG® was given to breast feeding mothers or straight to the child in water. After two years, the frequency of atopic eczema and allergies in the LGG® group was half that of the placebo group (Figure One).1 The mechanism is understood to be an increase in transforming anti-inflammatory growth factor (TGF-B2) in breast milk. TGF-B2 is a key immunoregulatory anti-inflammatory factor that inhibits IgE synthesis.3
Figure One: Incidence of Atopic Eczema with LGG®.1
Kalliomäki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet. 2001; 357(9262):1076-9.
- A randomised, double blind clinical trial of 31 infants with atopic eczema and a history of cow's milk allergy have shown that LGG® may reduce eczema associated symptoms such as itching and sleeplessness.4 The clinical symptom score of atopic dermatitis and digestive symptoms (SCORAD) decreased significantly after one month's intervention in infants receiving extensively hydrolysed whey infant formula with LGG®. The results showed that an improvement in endogenous barrier mechanism, via an alleviation of intestinal inflammation and reduced antigen absorption may assist in the relief of digestive symptoms associated with food allergies.4
- A review paper published in 'The Lancet', reported a significant reduction in the incidence of diarrhoea in adults with LGG® in five randomised, placebo-controlled trials.2 LGG® has also been shown to relieve and treat diarrhoea in several clinical trials. In a randomised controlled trial of 93 children, a significant reduction in duration of diarrhoea was reported.5This has also been supported in a separate study, where LGG® shortened the duration of diarrhoea from six days to three days.6
Figure Two: LGG® Has Been Shown to Relieve Diarrhoea.6
Guarino A, et al. Oral bacterial therapy reduces the duration of symptoms and of viral excretion in children with mild diarrhea. J Pediatr Gastroenterol Nutr 1997; 25(5):516-9.
- Ultra Flora LGG® contains a high strength and extensively trialled probiotic strain with supportive evidence from 215 research articles.7 LGG® has been shown to resist acid, bile and pancreatin digestion allowing survival through the digestive tract for colonisation.8
WARNING: If diarrhoea persists for more than six hours in infants under 6 months – 12 hours in children under 3 years – 24 hours in children aged 3-6 years or 48 hours in adults and children over 6 years – seek medical advice.
Proudly supporting the
Not all cautions and contraindications are listed. For full details, references or more information contact Health World Limited in Australia on 1800 777 648 or in New Zealand on 0508 227 744.
Adults: Take 2 capsules daily.
Mothers: Take 2 capsules daily during the last two months of pregnancy and during breastfeeding to reduce the frequency and severity of eczema and allergic rhinitis in their children.
Each capsule contains:
Lactobacillus rhamnosus (LGG®)
10 billion CFU (organisms)
Free from animal products, corn, dairy protein, lactose, eggs, gluten, wheat, nuts, yeast, soy protein and salt. Free from artificial colours, flavours and preservatives.
Store at 2°C to 8°C (Refrigerate. Do not freeze.)